Hereditary angioedema market was valued at $3,512.0 million in 2025 and is anticipated to reach approximately $8,421.3 million by 2035, registering a CAGR of 9.2% during the forecast period from 2026 to 2035. The hereditary angioedema market is strongly influenced by increasing diagnosis rates supported by improved genetic screening frameworks and rare disease awareness initiatives led by healthcare authorities. According to data from the US National Institutes of Health, hereditary angioedema is a rare autosomal dominant disorder caused by C1-inhibitor deficiency or dysfunction, requiring specialized diagnostic evaluation and long-term clinical management. Epidemiological assessments indicate a prevalence of nearly one case per 50,000 individuals, with some population studies reporting ranges between 1 in 50,000 and 1 in 100,000, highlighting a measurable yet historically underdiagnosed patient base. Increasing recognition among physicians and allergy specialists is contributing to earlier confirmation of cases that were previously misclassified as allergic angioedema.
Browse the full report description of “Hereditary Angioedema Market Size, Share and Trends Analysis Report, By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), By Route of Administration (Intravenous, Subcutaneous Injection, and Oral) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/hereditary-angioedema-market
Government-supported registries and scientific programs are also improving data collection, enabling better estimation of treatment demand. Rising awareness regarding the genetic nature of the disease is encouraging family screening, which directly increases the identified patient pool requiring preventive therapies. The long diagnostic delay historically associated with hereditary angioedema is gradually declining due to improved clinical guidelines and diagnostic protocols, strengthening demand for advanced targeted therapeutics.
Innovation Leaders Transforming the Hereditary Angioedema Market
The key players in the hereditary angioedema market include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pharming Group N.V., BioCryst Pharmaceuticals, Inc., and KalVista Pharmaceuticals, Inc., among others. These companies are advancing therapeutic innovation through the development of targeted biologics, plasma kallikrein inhibitors, and bradykinin pathway modulators aimed at improving disease control and long-term prophylaxis outcomes. Ongoing investments focus on oral and self-administered treatment options, extended dosing intervals, and improved safety profiles to enhance patient adherence. Strategic clinical programs and regulatory approvals are strengthening product pipelines while expanding treatment access. Continuous research into rare disease mechanisms and next-generation therapies is supporting the evolution of personalized treatment approaches within hereditary angioedema management.
Market Coverage
Key questions addressed by the report.
Global Hereditary Angioedema Market Report Segment
By Drug Class
By Route of Administration
Global Hereditary Angioedema Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hereditary-angioedema-market